CAR-T Cellular Therapy Development
CAR-T Cellular Therapy Solutions
From optimizing CAR-T cell design and evaluating pre-clinical models to discovering response biomarkers and mechanisms of action, together we can advance the field of cellular therapy and improve the human condition.
- Optimize CAR-T cell method development
- Measure metabolic fitness and persistence
- Create manufacturing acceptance criteria
- Monitor post-infusion exhaustion and toxicity
- Explore the response of the tumor microenvironment to CAR-T cells in solid tumors
- Measure changes in the solid tumor microenvironment
- Quantify CAR-T cell exhaustion
- Understand mechanisms of immune cell exhaustion
- Discover biomarkers for exhaustion
- Develop treatments to prevent or reverse immune cell exhaustion
- Spatially evaluate pre-clinical solid tumor models
- Visualize CAR-T cell trafficking within the tumor microenvironment
- Discover biomarkers for responders/non-responders
Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.
The adoptive transfer of regulatory T-cells (Tregs) is a promising therapeutic approach in transplantation and autoimmunity. However, because large cell numbers are needed to achieve a therapeutic effect, in vitro expansion is required.
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss.
A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.
Background aims: Next-generation immune cell therapy products will require complex modifications using engineering technologies that can maintain high levels of cell functionality. Non-viral engineering methods have the potential to address limitations associated with viral vectors.